Found: 8
Select item for more details and to access through your institution.
Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: A population‐based analysis in response to CVS 2022 formulary changes.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. E173, doi. 10.1002/ajh.26494
- By:
- Publication type:
- Article
The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation.
- Published in:
- Journal of Intensive Care, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40560-023-00672-5
- By:
- Publication type:
- Article
How to manage coagulopathies in critically ill patients.
- Published in:
- Intensive Care Medicine, 2023, v. 49, n. 3, p. 273, doi. 10.1007/s00134-023-06980-6
- By:
- Publication type:
- Article
NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis.
- Published in:
- Cardiovascular Research, 2023, v. 119, n. 11, p. 2046, doi. 10.1093/cvr/cvad084
- By:
- Publication type:
- Article
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 3, p. 330, doi. 10.1007/s12185-021-03078-x
- By:
- Publication type:
- Article
Recent advances in the research and management of sepsis-associated DIC.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 1, p. 24, doi. 10.1007/s12185-020-03053-y
- By:
- Publication type:
- Article
The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
- Published in:
- Inflammation Research, 2020, v. 69, n. 12, p. 1181, doi. 10.1007/s00011-020-01401-6
- By:
- Publication type:
- Article
The unique characteristics of COVID-19 coagulopathy.
- Published in:
- 2020
- By:
- Publication type:
- journal article